| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ... The Lancet 376 (9747), 1147-1154, 2010 | 3973 | 2010 |
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ... The Lancet 376 (9747), 1147-1154, 2010 | 3941 | 2010 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1030 | 2013 |
| Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study SJ Hotte, EW Winquist, E Lamont, M MacKenzie, E Vokes, EX Chen, ... Journal of Clinical Oncology 23 (3), 585-590, 2005 | 305 | 2005 |
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ... European urology 65 (3), 577-584, 2014 | 250 | 2014 |
| Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database … N Kroeger, W Xie, JL Lee, GA Bjarnason, JJ Knox, MJ MacKenzie, ... Cancer 119 (16), 2999-3006, 2013 | 231 | 2013 |
| Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy DY Heng, MJ Mackenzie, UN Vaishampayan, GA Bjarnason, JJ Knox, ... Annals of oncology 23 (6), 1549-1555, 2012 | 152 | 2012 |
| Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials DYC Heng, TK Choueiri, BI Rini, J Lee, T Yuasa, SK Pal, S Srinivas, ... Annals of oncology 25 (1), 149-154, 2014 | 149 | 2014 |
| Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study LC Harshman, W Xie, GA Bjarnason, JJ Knox, M MacKenzie, L Wood, ... The lancet oncology 13 (9), 927-935, 2012 | 137 | 2012 |
| A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer H Mackay, D Hedley, P Major, C Townsley, M Mackenzie, M Vincent, ... Clinical Cancer Research 11 (15), 5526-5533, 2005 | 131 | 2005 |
| The conundrum of low COVID-19 mortality burden in sub-Saharan Africa: myth or reality? J Adams, MJ MacKenzie, AK Amegah, A Ezeh, MA Gadanya, ... Global Health: Science and Practice 9 (3), 433-443, 2021 | 129 | 2021 |
| A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase … MJ Mackenzie, D Saltman, H Hirte, J Low, C Johnson, G Pond, MJ Moore Investigational new drugs 25, 553-558, 2007 | 103 | 2007 |
| Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer PA Tang, SJ Cohen, C Kollmannsberger, G Bjarnason, K Virik, ... Clinical Cancer Research 18 (21), 6023-6031, 2012 | 101 | 2012 |
| Molecular therapy in pancreatic adenocarcinoma MJ MacKenzie The lancet oncology 5 (9), 541-549, 2004 | 96 | 2004 |
| First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC JJ Ko, TK Choueiri, BI Rini, JL Lee, N Kroeger, S Srinivas, LC Harshman, ... British journal of cancer 110 (8), 1917-1922, 2014 | 90 | 2014 |
| The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database … FAB Schutz, W Xie, F Donskov, M Sircar, DF McDermott, BI Rini, ... European urology 65 (4), 723-730, 2014 | 89 | 2014 |
| Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy N Kroeger, TK Choueiri, JL Lee, GA Bjarnason, JJ Knox, MJ MacKenzie, ... European urology 65 (6), 1086-1092, 2014 | 88 | 2014 |
| A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer MJ MacKenzie, HW Hirte, G Glenwood, M Jean, R Goel, PP Major, ... Investigational new drugs 23, 165-170, 2005 | 79 | 2005 |
| Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic … MM Vickers, H Al-Harbi, TK Choueiri, C Kollmannsberger, S North, ... Clinical Genitourinary Cancer 11 (3), 311-315, 2013 | 78 | 2013 |
| A phase I study of temsirolimus and metformin in advanced solid tumours MJ MacKenzie, S Ernst, C Johnson, E Winquist Investigational new drugs 30, 647-652, 2012 | 63 | 2012 |
